Overview
The farnesoid X receptor (FXR), also known as NR1H4, is a nuclear receptor that functions as the primary bile acid sensor in the body. Activated by bile acids — especially chenodeoxycholic acid (CDCA) — FXR regulates bile acid synthesis, cholesterol metabolism, glucose homeostasis, and intestinal barrier integrity. Because gut bacteria determine which bile acids are present through deconjugation and transformation, the microbiome effectively controls FXR signaling, making this receptor a critical node in the gut-liver axis.
Bile Acid Activation
Primary bile acids synthesized in the liver (cholic acid, CDCA) are conjugated with taurine or glycine and secreted into the duodenum. Gut bacteria expressing bile salt hydrolase (BSH) — including blautia, bacteroides fragilis, lactobacillus, and bifidobacterium — deconjugate these bile acids, enabling further microbial transformation into secondary bile acids (deoxycholic acid, lithocholic acid).
FXR responds differently to these metabolites:
- CDCA — Most potent natural FXR agonist; drives protective anti-inflammatory signaling
- Cholic acid — Moderate agonist
- DCA, LCA — Weak FXR agonists; instead preferentially activate TGR5, which can drive pro-inflammatory IL-23 production
Dysbiosis that shifts bile acid composition from primary toward secondary bile acids therefore redirects signaling from FXR-dominant (protective) to TGR5-dominant (inflammatory) — a mechanism implicated in colorectal cancer, type 2 diabetes, and hepatic steatosis.
Metabolic Functions
FXR activation orchestrates a broad metabolic program:
- Bile acid homeostasis: FXR induces FGF15/19 in the ileum, which travels to the liver and suppresses CYP7A1 (the rate-limiting enzyme in bile acid synthesis), preventing toxic bile acid accumulation
- Glucose metabolism: Intestinal FXR activation improves insulin sensitivity and suppresses hepatic gluconeogenesis
- Lipid metabolism: FXR reduces hepatic triglyceride synthesis and promotes fatty acid oxidation
- Barrier integrity: FXR maintains tight junction protein expression and reduces intestinal permeability
- Immune regulation: FXR activation in intestinal immune cells suppresses NF-kB signaling, reducing inflammatory cytokine production
Cardiovascular Relevance
FXR agonist CDCA reduces blood pressure in spontaneously hypertensive rat models through iNOS expression, connecting bile acid sensing to vascular regulation [1]. This positions FXR at the intersection of gut microbiome composition, bile acid metabolism, and cardiovascular disease risk.
Microbiome Disruption of FXR
When dysbiosis depletes BSH-expressing commensals, conjugated bile acids accumulate and FXR activation is reduced. Specific patterns include:
- collinsella enrichment alters bile acid profiles, reducing hepatic bile acid synthesis via disrupted FXR signaling and promoting lipid accumulation
- clostridium symbiosum enrichment shifts the bile acid pool toward secondary bile acids with weak FXR but strong TGR5 activity
- odoribacter and blautia BSH activity supports FXR-activating bile acid pools; their depletion impairs FXR signaling
Cross-References
- bile acid metabolism — upstream process that determines FXR ligand availability
- blautia — BSH-expressing genus that modulates FXR signaling
- collinsella — disrupts FXR via altered bile acid profiles
- type 2 diabetes — FXR dysfunction contributes to insulin resistance
- hypertension — FXR agonists reduce blood pressure via iNOS